Organovo Holdings (Organovo Holdings) Days Sales Outstanding : 803.00 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Organovo Holdings Days Sales Outstanding?

Organovo Holdings's average Accounts Receivable for the three months ended in Dec. 2023 was $0.04 Mil. Organovo Holdings's Revenue for the three months ended in Dec. 2023 was $0.01 Mil. Hence, Organovo Holdings's Days Sales Outstanding for the three months ended in Dec. 2023 was 803.00.

The historical rank and industry rank for Organovo Holdings's Days Sales Outstanding or its related term are showing as below:

ONVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.09 Med: 62.21 Max: 149.95
Current: 140.27

During the past 12 years, Organovo Holdings's highest Days Sales Outstanding was 149.95. The lowest was 39.09. And the median was 62.21.

ONVO's Days Sales Outstanding is ranked worse than
76.38% of 889 companies
in the Biotechnology industry
Industry Median: 71.03 vs ONVO: 140.27

Organovo Holdings's Days Sales Outstanding increased from Dec. 2022 (52.94) to Dec. 2023 (803.00).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Organovo Holdings Days Sales Outstanding Historical Data

The historical data trend for Organovo Holdings's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organovo Holdings Days Sales Outstanding Chart

Organovo Holdings Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Days Sales Outstanding

Get a 7-Day Free Trial

81.83

51.03

149.95

Organovo Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															52.94	64.21	183.11	-	803.00

Competitive Comparison of Organovo Holdings's Days Sales Outstanding

For the Biotechnology subindustry, Organovo Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Organovo Holdings's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Organovo Holdings's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Organovo Holdings's Days Sales Outstanding falls into.

Organovo Holdings Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Organovo Holdings's Days Sales Outstanding for the fiscal year that ended in Mar. 2023 is calculated as

	Days Sales Outstanding (A: Mar. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Mar. 2022 )	+	Accounts Receivable (A: Mar. 2023 ))	/	count )	/	Revenue (A: Mar. 2023 )	*	Days in Period
=	( (0	+	0.152)	/	1 )	/	0.37	*	365
=	0.152					/	0.37	*	365
=	149.95

Organovo Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.055	+	0.033)	/	2 )	/	0.005	*	365 / 4
=	0.044					/	0.005	*	365 / 4
=	803.00

Organovo Holdings (NAS:ONVO) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Organovo Holdings Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Organovo Holdings's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Organovo Holdings (Organovo Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (NAS:ONVO) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

4OR1:Germany

Address

11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121

Website

https://www.organovo.com

Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.

Executives

David Gobel	director	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Vaidehi Joshi	director	C/O ORGANOVO HOLDINGS, INC., 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Alison Tjosvold Milhous	director	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Adam K Stern	director	STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Thomas Hess	officer: President, CFO and PFO	366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Douglas Jay Cohen	director	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Thomas E Jurgensen	officer: General Counsel & Secretary	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Jeffrey N. Miner	officer: Chief Scientific Officer	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Chris Heberlig	officer: President and CFO	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Keith Murphy	director, officer: Executive Chairman	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Steven George Hughes	officer: Chief Medical Officer	6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Carolyn Beaver	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David Shapiro	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Presnell Sharon Collins	officer: EVP, Research & Development	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Taylor Crouch	director, officer: CEO & President	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075